NASDAQ
20.51USD
+1.43 (+7.49%)
We have scored 21 news catalysts on STAAR Surgical Company (STAA) over the past 12 months. The biggest single-day move next to one of them came Apr 9, 2026, when STAA closed +20.7%: “STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid”. Coverage across the window leans positive (average ticker sentiment +0.14). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1B
P/E
—
EPS
—
Beta
1.22
52W range
15.59-35.87
Day range
19.70–20.75
Open
19.99
Prev close
19.08
Volume
1.3M
Avg volume
916.7K
Dividend
0.00
IPO
1992-02-24
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about STAAR Surgical Company — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of STAAR Surgical Company, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for STAA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
